In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...
HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...
Payers and employers have tightened access to the glucagon-like peptide-1 receptor agonist class once these therapies became ...
A new study has found that the groundbreaking new class of weight loss drugs may not only be good at treating diabetes, but ...
Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...
The United Kingdom will study whether the use of weight loss drugs could get people back to work. UK Health Minister Wes ...
Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...
Meanwhile, Hims & Hers tackles the GLP-1 shortage with a new app; Eli Lilly releases data on tirzepatide efficacy; 23andMe faces privacy concerns; and more.
Results from the SURMOUNT-1 trial show that weekly injections of tirzepatide could stop the progression from pre-diabetes to ...
With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...
Indianapolis-based Lilly has a research unit that does clinical trials on drugs for diabetes ... Data for tirzepatide, the ...
Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...